Carta Capital reaps 14-18% IRR on three exits
Lower mid-market mezzanine investor Carta Capital has exited three of its investments, each reaping an IRR of 14-18% and a money multiple of 1.6x to 1.8x.
More on UK / Ireland
ICG hires Bridge Valley's life sciences investment team
Allan Marchington, who will become head of ICG life sciences, says the team has a strong pipeline
Pantheon promotes four to partner
Petra Bukovec is a member of Pantheon's secondaries team and is based in London
Eight Roads promotes Cornet to partner
Principal Lucile Cornet joined Eight Roads Ventures as an associate in 2016
BGF invests £4m in CSN
For the year ending on 31 March 2020, the company generated £1.6m in EBITDA, from revenues of £27.1m
Latest News
LP Profile: IMCO
Managing director Craig Ferguson discusses accelerated deployment activity during the pandemic and plans to scale up the PE allocation by 2025
Elbrus holds first close on $260m for third fund – report
Fund has a target of $600m, which it plans to reach by next year, according to Kommersant
Alta Life Sciences invests in Inbiomotion
Existing investors including Institut Català de Finances also take part in the financing
Korys, FPIM et al. in €12m extended series-B for Remynd
Biotech company initially raised €12m in December 2018